Physician Guide
Non-Opioid Intrathecal Therapy Pain Medication
IMPORTANT SAFETY INFORMATION
WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS
PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.

Dosing and Titration of PRIALT

Page 1 of 2

Dr. Timothy R. Deer* discusses strategies for individualizing dosing with PRIALT. Dr. Deer is the President and CEO of The Center for Pain Relief, Inc. in Charleston, West Virginia.
 

 

Key Takeaway Points

PRIALT dosing should be individualized for each patient. As a general rule, all patients should be titrated slowly and individually based on effectiveness and tolerability. This may reduce the risk of serious adverse reactions and premature discontinuation due to adverse reactions. Remember to Start Low and Go Slow.

*Timothy R. Deer, MD is a paid consultant for Jazz Pharmaceuticals.

INDICATION
PRIALT® (ziconotide) intrathecal infusion (25mcg/mL, 100mcg/mL) is indicated for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.

©2016 Jazz Pharmaceuticals plc or its subsidiaries.
US-PRI-0186 REV 0916
Last updated on: June 20, 2017
SHOW MAIN MENU
SHOW SUB MENU